Breaking Finance News

A statement released earlier today by Citigroup about Zymeworks (NYSE:ZYME) bumps the target price to $18.00

Citigroup bumped up the target of Zymeworks (NYSE:ZYME) to $18.00 stating a potential upside of 0.38%.

Boasting a price of $13.06, Zymeworks (NYSE:ZYME) traded -6.89% lower on the day. With the last close up -16.99% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Zymeworks has recorded a 50-day average of $7.47 and a two hundred day average of $9.28. Volume of trade was up over the average, with 29,565 shares of ZYME changing hands over the typical 23,725

Performance Chart

Zymeworks (NYSE:ZYME)

With a total market value of $0, Zymeworks has with a one year low of $6.25 and a one year high of $14.25 .

More About Zymeworks (NYSE:ZYME)

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.